| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | Discapacidad visual
> Discapacidad visual | Asociación regulatoria
> Trabajando con organismos reguladores | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | Discapacidad visual
> Degeneración macular | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Neurológico
> Esclerosis múltiple | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | Respiratorio
> EPOC | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | Respiratorio
> Asma y alergia | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | Respiratorio
> Asma y alergia | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | Piel
> Afecciones cutáneas: la mayoría de los tipos | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | Cáncer
> Cáncer: sangre | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: la mayoría de los tipos | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | Gastrointestinal
> Gastrointestinal: la mayoría de los tipos | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | Cardiovascular
> Enfermedades cardiovasculares y del corazón | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Salud general
> Salud general | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | Cáncer
> Cáncer: piel | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 5000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Defensa del paciente
> Activista de salud | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defensa del paciente
> Activista de salud | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | Respiratorio
> Enfermedades pulmonares | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | Raro
> Enfermedades raras: otras | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 1000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cáncer
> Cáncer: mama | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cáncer
> Cáncer: la mayoría de los tipos | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 1000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Piel
> Alopecia | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 5000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorio
> Fibrosis pulmonar | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cáncer
> Cáncer: sangre | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 5000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | Cáncer
> Cáncer: vejiga | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | Discapacidad visual
> Discapacidad visual | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cáncer
> Cáncer: la mayoría de los tipos | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 1000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Enfermedad de Pompe | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | Respiratorio
> Fibrosis pulmonar | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cáncer
> Cáncer: colorrectal | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 10.000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salud general
> Obesidad | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | Salud general
> Obesidad | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | 100.000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | Educación del paciente
> Educación del paciente | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | Respiratorio
> Enfermedades pulmonares | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | Reumático
> Lupus | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Discapacidad visual
> Discapacidad visual | Asociación regulatoria
> Participar en evaluaciones de Evaluación de Tecnologías Sanitarias (ETS) y reembolso | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | Discapacidad
> Discapacidad: otra | Asociación regulatoria
> Contribuir a las presentaciones de Autorización de Comercialización | 5000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Personas mayores
> Personas mayores | Asociación regulatoria
> Asistir/facilitar reuniones con responsables políticos/reguladores | 100.000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cáncer
> Cáncer: mama | Asociación regulatoria
> Asistir/facilitar reuniones con responsables políticos/reguladores | 100.000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | Raro
> Enfermedades raras: sangre | Asociación regulatoria
> Asistir/facilitar reuniones con responsables políticos/reguladores | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | Sangre
> Enfermedad de células falciformes | Asociación regulatoria
> Con otros defensores de la salud | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Discapacidad visual
> Degeneración macular | Impactando en políticas y legislación
> Influir en la política sanitaria y la legislación | 100.000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Personas mayores
> Personas mayores | Impactando en políticas y legislación
> Influir en la política sanitaria y la legislación | 10.000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | Piel
> Afecciones cutáneas: la mayoría de los tipos | Impactando en políticas y legislación
> Participar en audiencias públicas y consultas | 100.000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | Reumático
> Esclerodermia | Impactando en políticas y legislación
> Participar en audiencias públicas y consultas | 5000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | Raro
> Enfermedades raras: genéticas | Impactando en políticas y legislación
> Movilizar parlamentarios y líderes políticos | 1000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Personas mayores
> Personas mayores | Impactando en políticas y legislación
> Movilizar parlamentarios y líderes políticos | 100.000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Personas mayores
> Personas mayores | Impactando en políticas y legislación
> Movilizar parlamentarios y líderes políticos | 10.000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cáncer
> Cáncer: sangre | Impactando en políticas y legislación
> Abordando barreras/anomalías en la atención médica | 1000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Discapacidad visual
> Discapacidad visual | Impactando en políticas y legislación
> Abordando barreras/anomalías en la atención médica | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cáncer
> Cáncer: sangre | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | 5000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Defensa del paciente
> Activista de salud | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurológico
> Epilepsia | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cáncer
> Cáncer: la mayoría de los tipos | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | 1000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | Cáncer
> Cáncer: sangre | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | 5000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Enfermedad de Pompe | Defensa de precios y asequibilidad
> Abogar por precios justos de los medicamentos | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cáncer
> Cáncer: sangre | Defensa de precios y asequibilidad
> Participar en negociaciones con el comité de revisión de precios | 5000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | Inmune
> Inmunodeficiencias primarias | Defensa de precios y asequibilidad
> Participar en negociaciones con el comité de revisión de precios | 5000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Personas mayores
> Personas mayores | Defensa de precios y asequibilidad
> Participar en negociaciones con el comité de revisión de precios | 10.000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | Discapacidad visual
> Discapacidad visual | Defensa de precios y asequibilidad
> Participar en negociaciones con el comité de revisión de precios | 100.000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | Cáncer
> Cáncer: sangre | Defensa de precios y asequibilidad
> Llamada para precios de venta reducidos de los fabricantes | 10.000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Inmune
> Inmunodeficiencias primarias | Defensa de precios y asequibilidad
> Seguimiento y monitorización de precios de medicamentos/escasez de medicamentos | 5000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurológico
> Epilepsia | Defensa de precios y asequibilidad
> Seguimiento y monitorización de precios de medicamentos/escasez de medicamentos | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cáncer
> Cáncer: la mayoría de los tipos | Defensa de precios y asequibilidad
> Seguimiento y monitorización de precios de medicamentos/escasez de medicamentos | 1000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | Salud mental
> Salud mental: trastornos del estado de ánimo | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | 10.000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Inmune
> Inmunodeficiencias primarias | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | 5000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | Neurológico
> Epilepsia | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratorio
> Fibrosis pulmonar | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | 100.000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | Discapacidad visual
> Discapacidad visual | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Enfermedad de Pompe | Defensa de precios y asequibilidad
> Abogando por la inclusión del producto en listas de reembolso/formularios nacionales | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | Piel
> Afecciones cutáneas: la mayoría de los tipos | Defensa de precios y asequibilidad
> Participar en campañas de concienciación | 100.000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cáncer
> Cáncer: sangre | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 1000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | Reumático
> Lupus | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 5000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Defensa del paciente
> Activista de salud | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | Raro
> Enfermedades raras: otras | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 1000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurológico
> Epilepsia | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cáncer
> Cáncer: la mayoría de los tipos | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 1000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cáncer
> Cáncer: sangre | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 5000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | Discapacidad visual
> Discapacidad visual | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | Cáncer
> Cáncer: sangre | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 5000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salud general
> Obesidad | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | 100.000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | Reumático
> Lupus | Mejora de las vías de acceso
> Facilitar el acceso equitativo a medicamentos/atención sanitaria | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Personas mayores
> Personas mayores | Mejora de las vías de acceso
> Abogar por un acceso más amplio a las vacunas | 10.000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | Discapacidad visual
> Discapacidad visual | Mejora de las vías de acceso
> Abordar las disparidades en el acceso y la gestión | 100.000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | Cáncer
> Cáncer: sarcoma | Mejora de las vías de acceso
> Mejora del acceso a terapias raras/ultrararas | 5000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Defensa del paciente
> Activista de salud | Aportaciones del paciente basadas en evidencia
> Utiliza los conocimientos del paciente para tomar decisiones | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Piel
> Alopecia | Aportaciones del paciente basadas en evidencia
> Utiliza los conocimientos del paciente para tomar decisiones | 5000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Enfermedad de Pompe | Aportaciones del paciente basadas en evidencia
> Utiliza los conocimientos del paciente para tomar decisiones | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Salud general
> Obesidad | Aportaciones del paciente basadas en evidencia
> Utiliza los conocimientos del paciente para tomar decisiones | 100.000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defensa del paciente
> Activista de salud | Aportaciones del paciente basadas en evidencia
> Proporcionar evidencia del mundo real (RWE) a las agencias reguladoras | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | Reumático
> Lupus | Aportaciones del paciente basadas en evidencia
> Aprovechar las historias de pacientes y los relatos de experiencias vividas | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Salud general
> Salud general | Aportaciones del paciente basadas en evidencia
> Aprovechar las historias de pacientes y los relatos de experiencias vividas | 10.000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defensa del paciente
> Activista de salud | Aportaciones del paciente basadas en evidencia
> Aprovechar las historias de pacientes y los relatos de experiencias vividas | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | Cáncer
> Cáncer: la mayoría de los tipos | Aportaciones del paciente basadas en evidencia
> Aprovechar las historias de pacientes y los relatos de experiencias vividas | 1000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cáncer
> Cáncer: la mayoría de los tipos | Aportaciones del paciente basadas en evidencia
> Aprovechar las historias de pacientes y los relatos de experiencias vividas | 1000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defensa del paciente
> Activista de salud | Aportaciones del paciente basadas en evidencia
> Realizar encuestas/investigaciones para generar datos | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | Discapacidad visual
> Discapacidad visual | Aportaciones del paciente basadas en evidencia
> Realizar encuestas/investigaciones para generar datos | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | VIH
> VIH y salud sexual | Gobernanza institucional
> Garantizar la representación en los órganos consultivos gubernamentales | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: la mayoría de los tipos | Gobernanza institucional
> Garantizar la representación en los órganos consultivos gubernamentales | 100.000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | Personas mayores
> Personas mayores | Gobernanza institucional
> Garantizar la representación en los órganos consultivos gubernamentales | 10.000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | Cáncer
> Cáncer: sangre | Gobernanza institucional
> Garantizar la representación en los órganos consultivos gubernamentales | 5000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | Cáncer
> Cáncer: sarcoma | Gobernanza institucional
> Garantizar la representación en los órganos consultivos gubernamentales | 5000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurológico
> Epilepsia | Gobernanza institucional
> Trabajar de manera efectiva dentro de redes con múltiples partes interesadas | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | VIH
> VIH y salud sexual | Defender los derechos del paciente/mejorar la calidad de vida
> Proteger/mejorar la experiencia del paciente | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | VIH
> VIH | Defender los derechos del paciente/mejorar la calidad de vida
> Proteger/mejorar la experiencia del paciente | 1000 | Local | Regularly | 119045557717 |
interacciones
acciones y defensa
36 menciones
